0001214659-23-017028.txt : 20231228 0001214659-23-017028.hdr.sgml : 20231228 20231228170700 ACCESSION NUMBER: 0001214659-23-017028 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231201 FILED AS OF DATE: 20231228 DATE AS OF CHANGE: 20231228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAZIMI A J CENTRAL INDEX KEY: 0001075050 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 231523406 MAIL ADDRESS: STREET 1: 1207 17TH AVENUE SUITE 103 CITY: NASHVILLE STATE: TN ZIP: 37212 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 marketforms-63937.xml PRIMARY DOCUMENT X0508 4 2023-12-01 0001087294 CUMBERLAND PHARMACEUTICALS INC CPIX 0001075050 KAZIMI A J 1600 WEST END AVE. SUITE 1300 NASHVILLE TN 37203 true true true false Chairman and CEO 1 Common Stock 2023-12-01 5 L false E 72 1.69 A 5720165 D Common Stock 2023-12-04 5 L false E 64 1.72 A 5720229 D Common Stock 2023-12-05 5 L false E 72 1.69 A 5720301 D Common Stock 2023-12-06 5 L false E 72 1.70 A 5720373 D Common Stock 2023-12-07 5 L false E 34 1.65 A 5720407 D Common Stock 2023-12-08 5 L false E 72 1.83 A 5720479 D Common Stock 2023-12-11 5 L false E 82 1.85 A 5720561 D Common Stock 2023-12-12 5 L false E 87 1.77 A 5720648 D Common Stock 2023-12-13 5 L false E 82 1.80 A 5720730 D Common Stock 2023-12-14 5 L false E 82 1.86 A 5720812 D Common Stock 2023-12-15 5 L false E 82 1.89 A 5720894 D Common Stock 2023-12-18 5 L false E 81 1.80 A 5720975 D Common Stock 2023-12-19 5 L false E 81 1.73 A 5721056 D Common Stock 2023-12-20 5 L false E 124 1.76 A 5721180 D Common Stock 2023-12-21 5 L false E 87 1.70 A 5721267 D The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May16, 2023. A.J. Kazimi by /s/ John Hamm as attorney-in-fact 2023-12-28